From Bench to Bedside-Delivering Gene Therapy for Leber Hereditary Optic Neuropathy.
Journal
Cold Spring Harbor perspectives in medicine
ISSN: 2157-1422
Titre abrégé: Cold Spring Harb Perspect Med
Pays: United States
ID NLM: 101571139
Informations de publication
Date de publication:
21 07 2022
21 07 2022
Historique:
pmc-release:
01
06
2024
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Leber hereditary optic neuropathy (LHON) is a rare, maternally inherited mitochondrial disorder that presents with severe bilateral sequential vision loss, due to the selective degeneration of retinal ganglion cells (RGCs). Since the mitochondrial genetic basis for LHON was uncovered in 1988, considerable progress has been made in understanding the pathogenetic mechanisms driving RGC loss, which has enabled the development of therapeutic approaches aimed at mitigating the underlying mitochondrial dysfunction. In this review, we explore the genetics of LHON, from bench to bedside, focusing on the pathogenetic mechanisms and how these have informed the development of different gene therapy approaches, in particular the technique of allotopic expression with adeno-associated viral vectors. Finally, we provide an overview of the recent gene therapy clinical trials and consider the unanswered questions, challenges, and future prospects.
Identifiants
pubmed: 35863905
pii: 12/6/a041282
doi: 10.1101/cshperspect.a041282
pmc: PMC9310952
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0701386
Pays : United Kingdom
Organisme : Department of Health
ID : BRC-1215-20014
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR301696
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1002570
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Cold Spring Harbor Laboratory Press; all rights reserved.